Eytan M Stein Selected Research

enasidenib

3/2024	Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
10/2023	A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
12/2022	Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
11/2021	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
1/2021	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
1/2021	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
4/2020	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
11/2019	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
1/2019	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
1/2018	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eytan M Stein Research Topics

Disease

47	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 07/2012
19	Neoplasms (Cancer) 03/2024 - 07/2015
9	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 01/2017
7	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2023 - 04/2020
7	Acute Promyelocytic Leukemia 01/2023 - 07/2012
7	Leukemia 11/2022 - 11/2017
3	Residual Neoplasm 12/2019 - 01/2016
3	Hemorrhage 03/2017 - 09/2013
2	Thrombocytopenia (Thrombopenia) 11/2021 - 01/2017
1	Hematologic Diseases (Blood Diseases) 03/2024
1	Primary Myelofibrosis (Myelosclerosis) 01/2024
1	Cytopenia 01/2023
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Neoplasm Metastasis (Metastasis) 01/2023
1	Exanthema (Rash) 12/2022
1	Disease Progression 11/2022
1	Necrotizing Pneumonia 03/2022
1	scedosporiosis 03/2022
1	Infections 03/2022
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 03/2022
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2022
1	Chest Pain (Chest Pains) 11/2021
1	Pericarditis 11/2021
1	Febrile Neutropenia 11/2021
1	Neutropenia 11/2021
1	Pneumonia (Pneumonitis) 11/2021
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2019
1	Carcinogenesis 12/2018
1	Fever (Fevers) 09/2018
1	Disease Resistance 01/2018
1	Hyperbilirubinemia 10/2017
1	Myocardial Infarction 01/2017
1	Glioma (Gliomas) 01/2016
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2016
1	Chondrosarcoma 01/2016
1	Skin Neoplasms (Skin Cancer) 10/2015
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 07/2015

Drug/Important Bio-Agent (IBA)

16	enasidenibIBA 03/2024 - 01/2016
10	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2023 - 10/2017
7	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2018
7	ivosidenibIBA 01/2023 - 01/2020
6	venetoclaxIBA 01/2023 - 10/2020
5	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 01/2017
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2021 - 07/2012
3	Heme (Haem)IBA 03/2024 - 10/2023
3	Decitabine FDA Link 01/2023 - 01/2021
3	Protein Isoforms (Isoforms)IBA 12/2018 - 01/2016
2	Cell-Free Nucleic AcidsIBA 03/2024 - 03/2022
2	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 10/2023
2	RNA Splicing FactorsIBA 12/2023 - 10/2019
2	Retinoic Acid Receptor alphaIBA 08/2023 - 01/2023
2	Biomarkers (Surrogate Marker)IBA 08/2023 - 11/2021
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 01/2021
2	EnzymesIBA 01/2021 - 01/2016
2	isocitric acid (isocitrate)IBA 04/2020 - 01/2019
2	Immunoconjugates (Immunoconjugate)IBA 01/2018 - 01/2016
1	quizartinibIBA 04/2024
1	TabletsIBA 01/2024
1	SulfonamidesIBA 12/2023
1	N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamideIBA 12/2023
1	tamibaroteneIBA 08/2023
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 01/2023
1	vorasidenibIBA 01/2023
1	Hemoglobins (Hemoglobin)IBA 01/2023
1	Messenger RNA (mRNA)IBA 01/2023
1	siremadlinIBA 03/2022
1	SolutionsIBA 03/2022
1	cilgavimabIBA 01/2022
1	Arsenic Trioxide (Trisenox)FDA Link 01/2022
1	cilgavimab and tixagevimab drug combinationIBA 01/2022
1	tixagevimabIBA 01/2022
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020
1	Transcription Factors (Transcription Factor)IBA 10/2020
1	Lysine (L-Lysine)FDA Link 10/2020
1	Exportin 1 ProteinIBA 08/2020
1	selinexorIBA 08/2020
1	Phenobarbital (Luminal)FDA Link 01/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	alpha-hydroxyglutarateIBA 12/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2018
1	Mesylates (Mesylate)IBA 01/2018
1	vadastuximab talirineIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017
1	telomerase RNA (bTR)IBA 01/2016
1	VemurafenibIBA 10/2015

Therapy/Procedure

25	Therapeutics 08/2023 - 02/2012
10	Drug Therapy (Chemotherapy) 01/2023 - 07/2012
4	Induction Chemotherapy 04/2024 - 06/2018
4	Stem Cell Transplantation 01/2021 - 01/2019
3	Hematopoietic Stem Cell Transplantation 01/2021 - 08/2012
2	Salvage Therapy 01/2023 - 12/2021
2	Precision Medicine 12/2020 - 01/2019
2	Consolidation Chemotherapy 06/2018 - 08/2012
1	Aftercare (After-Treatment) 01/2023
1	Cell Transplantation 01/2021
1	Immunotherapy 12/2019
1	Blood Transfusion (Blood Transfusions) 09/2018
1	Intravenous Infusions 01/2018
1	Transplantation 11/2017